Devon shedlock poseida
WebLinked companies : Poseida Therapeutics, Inc. Summary. Devon J. Shedlock is Chief Scientific Officer-Cell Therapies at Poseida Therapeutics, Inc. He received an undergraduate degree from Ursinus College and a doctorate from the University of Pennsylvania. Current positions of Devon J. Shedlock. WebOct 13, 2024 · SAN DIEGO, Oct. 13, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced appointments to new roles on its executive leadership team. …
Devon shedlock poseida
Did you know?
WebIn addition, Dr. Devon Shedlock, Senior Vice President, Research & Development at Poseida, has invented a technology that we call the booster molecule, which uniquely allows Poseida to maintain the Tscm cells in our fully allogeneic products, while expanding the cells to create hundreds of doses from a single manufacturing run from a single ... WebDevon Shedlock; Poseida, San Diego, CA, USA; Abstract. Background MUC1 is a highly glycosylated protein that is expressed at the apical border of mucosal epithelium where it plays a protective role. MUC1 is comprised of an N-terminal subunit (MUC1N) tethered to a C-terminal subunit (MUC1C), forming a stable complex on the cell surface. A ...
WebAug 23, 2024 · A Georgia special prosecutor determined that the two Atlanta police officers involved in the fatal shooting of Rayshard Brooks in June 2024 acted reasonably and … WebLinked companies : Poseida Therapeutics, Inc. Summary. Devon J. Shedlock is Chief Scientific Officer-Cell Therapies at Poseida Therapeutics, Inc. He received an …
WebIn the OVCAR3 xenograft model, intraperitoneally administered MUC1C CAR-T eliminated established tumor cells to levels below the limit of detection.ConclusionsP-MUC1C-ALLO1 is Poseida's allogeneic CAR TSCM product that has a potential to treat multiple MUC1-expressing indications. WebPoseida Awarded $3.99 Million CIRM Grant to Support Preclinical Development of P-PSMA-101, a T Stem Cell Memory CAR-T Therapy for Prostate Cancer. ... Devon J Shedlock’s Post ...
WebJan 24, 2024 · Dr Devon Shedlock is Poseida’s Chief Scientific Officer, Cell Therapy and was its first employee in 2015. He is a key scientific contributor in the application of the company’s proprietary gene engineering platform technologies to develop novel cell therapy programmes. Before joining Poseida, he held positions as an adjunct assistant ...
WebOct 13, 2024 · Joining Poseida as its first employee in 2015, Dr. Shedlock was most recently Senior Vice President of Research & Development, serving as a key scientific … flume red rocks axsWebDevon J. Shedlock's 20 research works with 282 citations and 1,878 reads, including: 46P Development of an allogeneic CAR-T targeting MUC1-C (MUC1, cell surface associated, … greenfield care center fullerton caWeb"We are pleased to present preclinical data from our anti-c-kit CAR-T program demonstrating the broad capabilities of our platform technologies to potentially improve patient outcomes," said Devon Shedlock, Ph.D., Chief Scientific Officer, Cell Therapies at Poseida Therapeutics. "P-ckit-ALLO1 is an allogeneic or 'off-the-shelf' adoptive cell … flume red rocks 2022WebOct 14, 2024 · Devon J. Shedlock, PhD, chief scientific officer, cell therapy, at Poseida Therapeutics, gave a presentation entitled “A Fully Allogeneic T scm-based TCR-T Platform for Cncology & Beyond” on Poseida’s … greenfield care center fullertonWebAug 3, 2024 · "We are thrilled that Roche has embraced the opportunity to partner with us and use Poseida's unique allogeneic approach to develop CAR-T product candidates," said Devon J. Shedlock, Ph.D., Chief Scientific Officer, Cell Therapy at Poseida. "Using our proprietary technologies and manufacturing process including our booster molecule, we … flume red rocksgreenfield care center of fairfield llcWebNov 9, 2024 · "We are pleased to share preclinical data for P-BCMA-ALLO1 and P-MUC1C-ALLO1, our first fully allogeneic candidates," said Devon Shedlock, Ph.D., Chief Scientific Officer, Cell Therapies at Poseida Therapeutics."The results being shared at SITC not only demonstrate potent antitumor efficacy in preclinical models for our allogeneic product … greenfield care center of fillmore llc